Japan, South Korea, and the United Kingdom (notably Moorfields Eye Hospital and other major research centres) are leading in human retinal cell-therapy trials. Switzerland offers private treatment at premium cost (€12,000–20,000). The United States has active research programmes but limited commercial availability.
Cell therapy for macular degeneration remains expensive and largely experimental. Treatment costs range from €6,000 to €15,000+ per eye, reflecting iPSC derivation, long-term cell expansion, quality-control testing, and the technical complexity of subretinal or intravitreal injection. Baseline and follow-up imaging (optical coherence tomography [OCT], visual field testing, electroretinography) adds €2,000–4,000. The condition typically affects both eyes, so bilateral treatment approaches €15,000–30,000.
Am I a candidate? → · Macular Degeneration & Vision: full overview → · Macular Degeneration & Vision cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.
Evaluare medicală gratuită